CompletedNot Applicable

Splenic Artery Ligation and Portocaval Shunt in Small-for-size Syndrome

Greece13 participantsStarted 2017-01-01

Plain-language summary

Our study aimed at assessing the changes of portal vein pressure, portal vein flow and hepatic arterial flow (HAF) in liver remnants ≤ 30% of the standard liver volume by reducing portal vein overflow via ligation of the splenic artery.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patients * American Society of Anesthesiologists (ASA) distribution I to III * Patients scheduled for major liver resection (≥4 segments) Exclusion Criteria: * patients with extrahepatic disease * patients with metastatic liver tumors

What they're measuring

portal vein pressure

Timeframe: through the operation, an average period of two hours

portal vein flow

Timeframe: through the operation, an average period of two hours

hepatic artery flow

Timeframe: through the operation, an average period of two hours

Trial details

NCT IDNCT05459883

SponsorAretaieion University Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-12-31

View on ClinicalTrials.gov More Small-For-Size Liver Syndrome trials